Immunoconjugates are antibodies conjugated (joined) to a second molecule, usually a toxin, radioisotope or label.1
These conjugates are used in immunotherapy and to develop monoclonal antibody therapy as a targeted form of chemotherapy2 when they are often known as antibody-drug conjugates.
Immunoconjugates that include a radioisotope are used in radioimmunotherapy. When immunoconjugates include a toxin, they are known as immunotoxins.
References
References
- Goldenberg DM, Sharkey RM (2007). "Novel radiolabeled antibody conjugates". Oncogene. 26 (25): 3734–44. doi:10.1038/sj.onc.1210373. PMID 17530026.
- Khandare JJ, Minko T (2006). "Antibodies and peptides in cancer therapy". Critical Reviews in Therapeutic Drug Carrier Systems. 23 (5): 401–35. doi:10.1615/CritRevTherDrugCarrierSyst.v23.i5.20. PMID 17425513.
Further reading
Further reading
- Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. 2007 looks useful from the abstract.
- Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. 2006 full article, 18 pages.
- Arming antibodies: prospects and challenges for immunoconjugates. 2005 10 pages.